Clinical Reviews in Allergy & Immunology

, Volume 34, Issue 1, pp 111–117 | Cite as

Rituximab as a Therapeutic Tool in Severe Mixed Cryoglobulinemia

  • Dario Roccatello
  • Simone Baldovino
  • Daniela Rossi
  • Osvaldo Giachino
  • Morteza Mansouri
  • Carla Naretto
  • Debora Di Simone
  • Simona Francica
  • Roberto Cavallo
  • Mirella Alpa
  • Franca Napoli
  • Luigi M. Sena
Article

Abstract

Type II mixed cryoglobulinemia (MC) is a systemic vasculitis, associated in most cases with hepatitis C virus (HCV) infection, sustained by proliferation of oligoclonal cells. Systemic B cell depletion and clinical remission can be achieved in non-Hodgkin lymphoma by human/mouse chimeric monoclonal antibody that specifically reacts with the CD20 antigen (rituximab). Similar effects could be expected in type II MC. Twelve patients, mean age 61.9 years (range 37–76), 11 with HCV infection genotype 2a2c (4 cases) or 1b (6 cases) and 3 (1 case) and symptomatic type II MC with systemic manifestations, including renal involvement, marrow clonal restriction, large necrotizing ulcers, and polyneuropathy, were considered eligible for rituximab therapy because of resistance or intolerance to conventional therapy or important bone marrow infiltration. Rituximab was administered intravenously at a dose of 375 mg/m2 on days 1, 8, 15, and 22. Two more doses were administered 1 and 2 months later. No other immunosuppressive drugs were added. Response was evaluated by assessing the changes in clinical signs, symptoms, and laboratory parameters. Levels of proteinuria, hematuria, erythrocyte sedimentation rate, cryocrit, rheumatoid factor, and IgM decreased while C4 values increased and HCV viral load remained stable during short- and medium-term observation. Bone marrow abnormalities were found to reverse to normal. Constitutional symptoms disappeared or ameliorated. No acute or delayed side effects were seen. Based on this experience and a number of reports published in the last 5 years, Rituximab appears to be a safe and effective therapeutic option in symptomatic patients with HCV-associated MC with signs of systemic vasculitis.

Keywords

Mixed cryoglobulinemia Cryoglobulinemic glomerulonephritis Rituximab Anti CD20 monoclonal antibody Cryoglobulins HCV syndrome 

References

  1. 1.
    Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M (1974) Biological and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57:775–778PubMedCrossRefGoogle Scholar
  2. 2.
    Meltzer M, Franklin EC, Elias K et al (1966) Cryoglobulinemia, a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 40:837–856PubMedCrossRefGoogle Scholar
  3. 3.
    Gorevic PD, Kassab HJ, Levo Y et al (1980) Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 69:287–308PubMedCrossRefGoogle Scholar
  4. 4.
    D’Amico G, Colasanti G, Ferrario F, Sinico RA (1989) Renal involvement in essential mixed cryoglobulinemia. Kidney Int 35:1004–1014PubMedCrossRefGoogle Scholar
  5. 5.
    Pascual M, Perrin L, Giostra E, Schifferli JA (1990) Hepatitis C virus in patients with cryoglobulinemia type II. Infectious Dis 162:569–575Google Scholar
  6. 6.
    Durand JM, Lefevre P, Harle JR et al (1991) Cutaneous vasculitis and cryoglobulinemia type II associated with hepatitis C virus infection. Lancet 337:499–500PubMedCrossRefGoogle Scholar
  7. 7.
    Casato M, Taliani G, Pucillo L et al (1991) Cryoglobulinemia and hepatitis C virus. Lancet 337:449–453CrossRefGoogle Scholar
  8. 8.
    Misiani R, Bellavita P, Fenili D et al (1992) Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 117:573–577PubMedGoogle Scholar
  9. 9.
    Ferri C, Longombardo G, La Civita L et al (1992) Hepatitis C virus, autoimmune liver disease and cryoglobulinemic hepatitis. J Hepatol 16:242–243PubMedCrossRefGoogle Scholar
  10. 10.
    Agnello V, Chung RT, Kaplan LM (1992) A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327:1490–1495PubMedCrossRefGoogle Scholar
  11. 11.
    Ferri C, Monti M, La Civita L et al (1993) Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 82:3701–3704PubMedGoogle Scholar
  12. 12.
    Invernizzi F, Pioltelli P, Cattaneo R et al (1979) A long-term follow-up study in essential cryoglobulinemia. Acta Haematol 61:93–99PubMedGoogle Scholar
  13. 13.
    Tarantino A, De Vecchi A, Montagnino G et al (1981) Renal disease in essential mixed cryoglobulinemia. Long term follow-up of 44 patients. Q J Med 50:1–30PubMedGoogle Scholar
  14. 14.
    Monti G, Galli M, Invernizzi F et al (1995) Cryoglobulinemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinemias. QJM 88:115–126PubMedGoogle Scholar
  15. 15.
    Rieu V, Cohen P, Andrè MH et al (2002) Characteristics and outcome of 49 patients. Rheumatology 41:290–300PubMedCrossRefGoogle Scholar
  16. 16.
    Tarantino A, Campise M, Banfi G et al (1995) Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 47:618–623PubMedCrossRefGoogle Scholar
  17. 17.
    Roccatello D, Fornasieri A, Giachino O et al (2007) Multicenter study on HCV-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 49:69–82PubMedCrossRefGoogle Scholar
  18. 18.
    Roccatello D, Isidoro C, Mazzucco G et al (1993) Role of monocytes in cryoglobulinemia-associated nephritis. Kidney Int 43:1150–1155PubMedCrossRefGoogle Scholar
  19. 19.
    Ferri C, Mascia MT (2006) Cryoglobulinemic vasculitis. Curr Opin Rheumatol 18:54–63PubMedCrossRefGoogle Scholar
  20. 20.
    Fornasieri A, Li M, Armelloni S et al (1993) Glomerulonephritis induced by human IgMk–IgG cryoglobulins in mice. Lab Invest 69:531–540PubMedGoogle Scholar
  21. 21.
    Roccatello D, Morsica G, Picciotto G et al (1997) Impaired hepatosplenic elimination of circulating cryoglobulins in patients with essential mixed cryoglobulinemia and hepatitis C virus (HCV) infection. Clin Exp Immunol 110:9–14PubMedCrossRefGoogle Scholar
  22. 22.
    Pileri P, Uematsu Y, Campagnoli S et al (1998) Binding of hepatitis C virus to CD81. Science 282:938–941PubMedCrossRefGoogle Scholar
  23. 23.
    Roccatello D, Giachino O, Fornasieri A (2000) Forum multidisciplinare su “la sindrome HCV”. G Ital Nefrol 6:654–665Google Scholar
  24. 24.
    Zignego AL, Giannelli F, Marrocchi ME et al (2000) T [14 18] translocation in chronic hepatitis C virus infection. Hepatology 31:474–479PubMedCrossRefGoogle Scholar
  25. 25.
    Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195PubMedGoogle Scholar
  26. 26.
    Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644–1652PubMedGoogle Scholar
  27. 27.
    Byrd JC, White CA, Link B et al (1999) Rituximab therapy in Waldenstrom’s macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 10:1525–1527PubMedCrossRefGoogle Scholar
  28. 28.
    Levine TD, Pestronk A (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 52:1701–1704PubMedGoogle Scholar
  29. 29.
    Saleh MN, Gutheil J, Moore M et al (2000) A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27:99–103PubMedGoogle Scholar
  30. 30.
    Zecca M, De Stefano P, Nobili B, Locatelli F (2001) Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 97:3995–3997PubMedCrossRefGoogle Scholar
  31. 31.
    Zaja F, De Vita S, Mazzaro C et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827–3834PubMedCrossRefGoogle Scholar
  32. 32.
    Zaja F, Russo D, Fuga G et al (1999) Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 84:1157–1158PubMedGoogle Scholar
  33. 33.
    Della Rossa A, Tavoni A, Baldini C, Bombardieri S (2002) Treatment of chronic hepatitis C infection with cryoglobulinemia. Curr Opin Rheum 13:231–237CrossRefGoogle Scholar
  34. 34.
    Misiani R, Bellavita P, Fenili D et al (1994) Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330:751–756PubMedCrossRefGoogle Scholar
  35. 35.
    Johnson RJ, Gretch DR, Couser WG et al (1994) Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 46:1700–1704PubMedCrossRefGoogle Scholar
  36. 36.
    Rossi P, Bertani T, Baio P et al (2003) Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 63:2236–2241PubMedCrossRefGoogle Scholar
  37. 37.
    Manns MP, McHutchison JG, Gordon SC et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965PubMedCrossRefGoogle Scholar
  38. 38.
    Lindsay KL, Trepo C, Heintges T et al (2001) A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395–403PubMedCrossRefGoogle Scholar
  39. 39.
    Selby P, Kohn J, Raymond J, Judson I, McElwain T (1985) Nephrotic syndrome during treatment with interferon. Br Med J 290:1180CrossRefGoogle Scholar
  40. 40.
    Janessen H, Brouwer J, Van der Mast RC, Schalm S (1994) Suicide associated with alpha-interferon therapy for chronic viral hepatitis. J Hepatol 21:241–243CrossRefGoogle Scholar
  41. 41.
    Ferri C, Pileri S, Zignego AL (2000) Hepatitis C virus, B-cell disorders, and non-Hodgkin lymphoma. In: Goedert JJ (ed) Infectious cause of cancer. Target for intervention. Humana, Totowa, pp 349–368CrossRefGoogle Scholar
  42. 42.
    Roccatello D, Mazzucco G, Coppo R et al (1991) Immune material processing by phagocyte cell system in cryoglobulinemia. Clin Nephrol 36:114–126PubMedGoogle Scholar
  43. 43.
    Margin S, Craxi A, Fabiano C et al (1994) Hepatitis C viraemia in chronic liver disease: relationship to interferon alpha or corticosteroid treatment. Hepatology 19:273–279Google Scholar
  44. 44.
    Roccatello D, Baldovino S, Rossi D et al (2004) Long term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinemic glomerulonephritis. Nephrol Dial Transplant 19:3054–3061PubMedCrossRefGoogle Scholar
  45. 45.
    Looney RJ (2002) Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 61:863–866PubMedCrossRefGoogle Scholar
  46. 46.
    Arzoo K, Sadeghi S, Liebman HA (2002) Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody Rituximab. Ann Rheum Dis 61:922–924PubMedCrossRefGoogle Scholar
  47. 47.
    Treon SP, Anderson KC (2000) The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders. Semin Oncol 27:79–85PubMedGoogle Scholar
  48. 48.
    Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443–446PubMedCrossRefGoogle Scholar
  49. 49.
    Sansonno D, De Re V, Lauretta G et al (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alfa with an anti-CD20. Blood 101:3818–3826PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Dario Roccatello
    • 1
  • Simone Baldovino
    • 2
  • Daniela Rossi
    • 1
  • Osvaldo Giachino
    • 1
  • Morteza Mansouri
    • 2
  • Carla Naretto
    • 1
  • Debora Di Simone
    • 2
  • Simona Francica
    • 2
  • Roberto Cavallo
    • 1
  • Mirella Alpa
    • 1
  • Franca Napoli
    • 2
  • Luigi M. Sena
    • 2
  1. 1.Centro Multidisciplinare di Ricerche di Immunopatologia e Documentazione su Malattie Rare, Struttura Complessa a Direzione Universitaria di Immunologia Clinica (CMID), Ospedale S.G. BoscoTorinoItaly
  2. 2.Dipartimento di Medicina e Oncologia Sperimentale, Sezione di Patologia GeneraleUniversità di TorinoTorinoItaly

Personalised recommendations